{"organizations": [], "uuid": "66258acd93239066ea105b4501316c990ae5c58b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-advanced-proteome-therapeutics-and/brief-advanced-proteome-therapeutics-and-immunobiochem-enter-into-collaboration-and-option-agreement-idUSFWN1PX12N", "country": "US", "domain_rank": 408, "title": "BRIEF-Advanced Proteome Therapeutics And Immunobiochem Enter Into Collaboration And Option Agreement", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.382, "site_type": "news", "published": "2018-02-07T21:35:00.000+02:00", "replies_count": 0, "uuid": "66258acd93239066ea105b4501316c990ae5c58b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-advanced-proteome-therapeutics-and/brief-advanced-proteome-therapeutics-and-immunobiochem-enter-into-collaboration-and-option-agreement-idUSFWN1PX12N", "ord_in_thread": 0, "title": "BRIEF-Advanced Proteome Therapeutics And Immunobiochem Enter Into Collaboration And Option Agreement", "locations": [], "entities": {"persons": [{"name": "immunob", "sentiment": "negative"}, {"name": "immunobiochem", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "advanced proteome therapeutics corp", "sentiment": "negative"}, {"name": "therapeutics corp", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 7 (Reuters) - Advanced Proteome Therapeutics Corp :\n* ADVANCED PROTEOME THERAPEUTICS AND IMMUNOBIOCHEM CORPORATION ENTER INTO A COLLABORATION AND OPTION AGREEMENT\n* ADVANCED PROTEOME THERAPEUTICS - CO, IMMUNOBIOCHEM ENTER INTO COLLABORATION AND OPTION AGREEMENT TO DEVELOP SUPERIOR ANTIBODY-DRUG CONJUGATES\n* ADVANCED PROTEOME THERAPEUTICS - IMMUNOBIOCHEM GRANTED RIGHTS TO LICENSE PROPRIETARY SITE-SELECTIVE CONJUGATION TECHNOLOGY\n* ADVANCED PROTEOME THERAPEUTICS CORP - PRE-NEGOTIATED LICENSING TERMS INCLUDE UPFRONT AND MILESTONE PAYMENTS AND ROYALTIES Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-07T21:35:00.000+02:00", "crawled": "2018-02-09T05:53:07.004+02:00", "highlightTitle": ""}